Figure 6
CTLA4 blockade markedly synergized with subsequent local delivery of LTX-315. (a) Experimental setting. Scheduling and routing of mAbs injections as detailed in Materials and Methods section. s.c., subcutaneous; i.p., intraperitoneal; i.t., intratumoral. (b and c) Tumor growth kinetics in the presence (right panel) or absence (left panel) of such immune checkpoint-targeting antibodies (anti-CTLA4: 100 μg/mouse or anti-PD-1 mAb: 250 μg/mouse, three injections each) or isotype control mAbs injected before LTX-315. The Kaplan–Meier curves are depicted in the right panels gathering two experiments. In all graphs, a representative experiment out of two comprising 6–7 mice per group is shown. Comparison of Kaplan–Meier survival curves were performed using the log-rank Mantel–Cox test: **P<0.01, ****P<0.0001; NS, not significant
